Save up -80% on Coagulation Factor IX (Recombinant)
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Benefix
|$346.65||1 kit (single dose) 250iu|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Benefix coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Coagulation Factor IX (Recombinant) every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Coagulation Factor IX (Recombinant) volume of distribution
In studies of the effect of EDTA on circulating factor IX concentrations, 40 μL of 0.5 M EDTA (pH 7.4) was injected into the jugular vein 11 minutes or 12 hours after factor IX injection. The final sample was taken 1 minute later. The volumes of the 2 compartments were calculated using the total steady-state volume of distribution.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Coagulation Factor IX (Recombinant)
Recombinant Coagulation Factor IX is a purified Factor IX glycoprotein produced by recombinant DNA technology. It has a primary amino acid sequence that is identical to the Ala148 allelic form of human factor IX, and has structural and functional characteristics similar to those of endogenous factor IX. It is not derived from human blood (unlike human Factor IX complex), and is instead produced by a genetically engineered Chinese hamster ovary (CHO) cell line that secretes recombinant Factor IX into cell medium that is then processed and purified for use as a pharmaceutical agent. ; ; Recombinant Factor IX is indicated for the control and prevention of bleeding episodes in adult and pediatric patients with congenital factor IX deficiency (Hemophilia B).
Coagulation Factor IX (Recombinant) mechanism of action
Coagulation Factor IX is an important protein in the process of hemostasis and normal blood clotting as it plays a key role within the coagulation cascade. It is located within the blood plasma as a zymogen, an antecedent to enzymatic function, in its inactivated state. Factor IX is dependent on the presence of Vitamin K, and is activated to a serine protease by the function of Coagulation Factor XIa. Factor XIa cleaves the peptide bond associated with protein activation in Factor IX, leaving Factor IX with two exposed chains, a light chain and a heavy chain. These two chains are held together by several disulfide bonds that reinforce the structure of Factor IX’s activated form. After being activated, Factor IX forms a complex with calcium ions, membrane phospholipids and Coagulation Factor VIII to activate Coagulation Factor X. The activation of Factor X then performs a similarly integral step in the blood coagulation cascade. The ultimate result of phenotypically normal coagulation factors is the creation of platelets for normal blood clotting.
Dosage forms of Coagulation Factor IX (Recombinant)
|Powder for solution||intravenous||1000 unit|
|Powder for solution||intravenous||2000 unit|
|Powder for solution||intravenous||250 unit|
Coagulation factor IX (recombinant) Coagulation factor IX recombinant human
Pfizer Canada Inc
Humans and other mammals
Indication of Coagulation Factor IX (Recombinant)
For treatment of hemophilia (Christmas disease).
Toxicity of Coagulation Factor IX (Recombinant)
High-capacity adenoviral vectors (HCAV) with episomic persistence, bearing no viral genes, are known to trigger a reduced immune response, and the use of a tissue-specific promoter (e.g. hepatic) can further diminish the response, therefore prolonging the gene expression period. HCAV with a liver-specific promoter has yielded therapeutic expression levels of IX with limited toxicity in hemophilic mice and hemophilic dogs, and yet a gradual decline in transgene expression was observed. Inhibitor antibodies, as well as hematologic and hepatic toxicities, were detected in animals injected at high vector doses, limiting the expression period to 446-604 days in dogs.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Coagulation Factor IX (Recombinant) on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.